ArticleDigestive diseases and sciences2022
Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis.
Article in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 13 citations in OpenAlex.
- A novel model for detecting advanced fibrosis in patients with nonalcoholic fatty liver disease.Diabetes/metabolism research and reviews · 2022Trial
- Personalized Management of Cytopenias in Chronic Liver Disease: From Pathophysiology to Treatment Strategies.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Interleukin 13 (IL-13) Signalling as a Potential Target for Cell Therapies in Liver Fibrosis.International journal of molecular sciences · 2026Review
- Effectiveness of controlled-expansion transjugular intrahepatic portosystemic shunt (CX-TIPS) in an interdisciplinary setting at a large tertiary center.Wiener klinische Wochenschrift · 2026Article
- Alcohol Use After TIPS Implantation Significantly Increases the Risk of ACLF and Liver-Related Death.United European gastroenterology journal · 2026Article
- Idiopathic portal hypertension with transfusion-associated hemolytic anemia: a case report.AME case reports · 2026Article
- Etiology-Specific Nomograms for Predicting First Variceal Bleeding in Decompensated HBV- and HCV-Related Cirrhosis.International journal of general medicine · 2026Article
- Effect of transjugular intrahepatic portosystemic shunt on platelet count and exact spleen volume segmented on computed tomography.Acta radiologica open · 2025Article
- Clinical application of preoperative volumetric measurement for interventional precise embolization in the treatment of hypersplenism caused by liver cirrhosis.BMC surgery · 2025Article
- Decreasing interleukin-6 levels after TIPS predict outcomes in decompensated cirrhosis.JHEP reports : innovation in hepatology · 2025Article
- The inflammatory index and cytokines are associated with non-alcoholic fatty liver disease in type 2 diabetes mellitus.Frontiers in medicine · 2025Article
- Efficacy of transjugular intrahepatic portosystemic shunts in treating cirrhotic esophageal-gastric variceal bleeding.World journal of gastrointestinal surgery · 2024Article
- The impact of thrombocytopenia on variceal bleeding in cirrhotic patients with transjugular intrahepatic portosystemic shunt.Scientific reports · 2023Article
- Noncirrhotic portal hypertension due to peripheral T-cell lymphoma, not otherwise specified: A case report.World journal of clinical cases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with cirrhosis often develop portal hypertension-associated splenomegaly and hypersplenism, potentially causing severe cytopenia.
aimsSystematic assessment on the impact of transjugular intrahepatic portosystemic shunt (TIPS) implantation on platelet count (PLT), hemoglobin (Hb), and white blood cell count (WBC).
methodsPatients with cirrhosis undergoing covered TIPS implantation were retrospectively included. Patients with malignancies or hematologic disorders were excluded. Hematology lab work was recorded at baseline (pre-TIPS) and at regular intervals after TIPS.
resultsOne hundred ninety-two patients (male: 72.4%, age: 56 ± 10 years; MELD: 12.1 ± 3.6) underwent TIPS implantation. Higher-grade (≥ G2) thrombocytopenia (PLT < 100 G/L) was present in 54 (28.7%), ≥ G2 anemia (Hb < 10 g/dL) in 57 (29.7%), and ≥ G2 leukopenia (WBC < 2 G/L) in 3 (1.6%) patients pre-TIPS, respectively. Resolution of ≥ G2 thrombocytopenia, anemia, and leukopenia occurred in 24/55 (43.6%), 23/57 (40.4%), and 2/3 (66.7%), respectively. Similar results were also observed in the subgroup of patients without 'bleeding' TIPS-indication, with improvements of G ≥ 2 thrombocytopenia and of G ≥ 2 anemia in 19.8% and 10.2% of patients after TIPS, respectively.
conclusionsThrombocytopenia, anemia, and leukopenia frequently improved after TIPS. Therefore, moderate- to higher-grade thrombocytopenia should not be regarded as a contraindication against TIPS, but rather be considered in case of severe thrombocytopenia-particularly prior to surgery or interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.